{"id":9236,"date":"2020-07-02T13:26:53","date_gmt":"2020-07-02T17:26:53","guid":{"rendered":"https:\/\/imedcprod.wpengine.com\/the-hill-times-lettre-a-lediteur\/"},"modified":"2020-07-02T13:26:53","modified_gmt":"2020-07-02T17:26:53","slug":"the-hill-times-lettre-a-lediteur","status":"publish","type":"post","link":"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/","title":{"rendered":"The Hill Times,<\/em>
Lettre \u00e0 l\u2019\u00e9diteur"},"content":{"rendered":"

Journal The Hill Times<\/em>
\nLettre \u00e0 l\u2019\u00e9diteur
\nPubli\u00e9e<\/a> le 1er juillet 2020<\/p>\n

Traduit de l\u2019anglais<\/em><\/p>\n

Objet\u00a0: <\/strong>La deuxi\u00e8me consultation du CEPMB sur les nouvelles r\u00e8gles d\u2019\u00e9tablissement des prix des m\u00e9dicaments portera sur l\u2019acc\u00e8s aux m\u00e9dicaments <\/strong><\/p>\n

Des donn\u00e9es r\u00e9centes provenant de diverses sources confirment ce que l\u2019industrie canadienne des m\u00e9dicaments novateurs soutient depuis plus de trois ans maintenant\u00a0: les changements apport\u00e9s r\u00e9cemment par Sant\u00e9 Canada au R\u00e8glement sur les m\u00e9dicaments brevet\u00e9s<\/em> du Conseil d\u2019examen du prix des m\u00e9dicaments brevet\u00e9s (CEPMB) auront un impact n\u00e9gatif sur l\u2019acc\u00e8s des patients aux m\u00e9dicaments, sur l\u2019investissement dans notre secteur des sciences de la vie et sur le lancement de nouveaux m\u00e9dicaments et vaccins au Canada.<\/p>\n

Depuis la publication du nouveau R\u00e8glement du CEPMB en ao\u00fbt dernier, les membres de M\u00e9dicaments novateurs Canada (MNC) ont signal\u00e9 plusieurs retards ou suspensions de lancement de m\u00e9dicaments, notamment pour les maladies rares et les m\u00e9dicaments oncologiques. L\u2019analyse par MNC des donn\u00e9es du Conference Board du Canada<\/a> (CBdC) confirme qu\u2019entre ao\u00fbt 2019 et mars 2020, 30 \u00e0 40\u00a0% moins de dossiers de nouveaux m\u00e9dicaments ont \u00e9t\u00e9 soumis \u00e0 Sant\u00e9 Canada pour approbation dans les 12 mois suivant la premi\u00e8re soumission mondiale, par rapport aux 3 ann\u00e9es pr\u00e9c\u00e9dentes (24\u00a0%); et deux fois plus de m\u00e9dicaments (42\u00a0%) d\u00e9j\u00e0 approuv\u00e9s par Sant\u00e9 Canada ont connu un retard dans leur lancement de plus de 6 mois, comparativement aux 3 ann\u00e9es pr\u00e9c\u00e9dentes. L\u2019analyse des donn\u00e9es du CBdC par MNC<\/a> a \u00e9galement montr\u00e9 qu\u2019au cours des onze mois ayant suivi la publication du nouveau R\u00e8glement, le Canada commence d\u00e9j\u00e0 \u00e0 constater une diminution de la part des essais cliniques de m\u00e9dicaments financ\u00e9s par l\u2019industrie mondiale. Une autre analyse r\u00e9cente<\/a> r\u00e9alis\u00e9e par IQVIA se penchant sur les lancements de nouveaux m\u00e9dicaments au Canada\u2014 l\u2019une des principales soci\u00e9t\u00e9s mondiales de donn\u00e9es sur les soins de sant\u00e9, les essais biopharmaceutiques et les essais cliniques \u2014 est parvenue \u00e0 une conclusion similaire\u00a0: 2019 a vu une baisse importante au Canada du nombre et de la part mondiale de lancements de nouveaux m\u00e9dicaments\u2014 \u00e0 moins de la moiti\u00e9 de ceux observ\u00e9s ces derni\u00e8res ann\u00e9es.<\/p>\n

De m\u00eame, une nouvelle \u00e9tude<\/u> \u00e9valu\u00e9e par les pairs publi\u00e9e cette semaine par l\u2019Institut canadien des politiques de sant\u00e9<\/a> r\u00e9fute les affirmations du CEPMB qu\u2019il n\u2019existe aucune preuve reliant les prix des m\u00e9dicaments \u00e0 l\u2019acc\u00e8s aux m\u00e9dicaments et aux investissements en R et D, Bien au contraire, l\u2019\u00e9conomiste en sant\u00e9 Yanick Labrie a effectu\u00e9 un examen d\u00e9taill\u00e9 de la litt\u00e9rature et a constat\u00e9 qu\u2019il existe en fait un grand nombre de preuves reliant directement les prix et la r\u00e9glementation des prix aux investissements en R et D et \u00e0 l\u2019acc\u00e8s aux nouveaux m\u00e9dicaments. Sur 49 \u00e9tudes ayant examin\u00e9 cette question pr\u00e9cise, 44 ont r\u00e9v\u00e9l\u00e9 qu\u2019il existe une relation n\u00e9gative importante entre le contr\u00f4le des prix des m\u00e9dicaments avec soit les investissements en R et D ou l\u2019acc\u00e8s aux m\u00e9dicaments ou les deux, ou une relation positive importante entre les niveaux de prix des m\u00e9dicaments avec soit les investissements en R et D ou l\u2019acc\u00e8s aux m\u00e9dicaments ou les deux.<\/p>\n

Cette recherche se joint \u00e0 d\u2019autres confirmant que les dangers d\u2019impact n\u00e9gatif des changements du CEPMB sont r\u00e9els et importants, non seulement pour le secteur des sciences de la vie au Canada, mais plus important encore, pour les millions de patients canadiens qui d\u00e9pendent de nouveaux m\u00e9dicaments et vaccins. Heureusement, il n\u2019est pas trop tard pour trouver une solution permettant d\u2019\u00e9viter ce r\u00e9sultat. L\u2019industrie est pr\u00eate \u00e0 offrir, comme nous le sommes depuis \u00a0ces trois derni\u00e8res ann\u00e9es, des alternatives qui \u00e9viteront les r\u00e9percussions n\u00e9gatives du R\u00e8glement modifi\u00e9, tout en permettant \u00e0 Sant\u00e9 Canada d\u2019atteindre ses objectifs de politique publique. Nous esp\u00e9rons que le gouvernement s\u2019av\u00e9rera un partenaire collaborateur.<\/p>\n

Pamela Fralick, pr\u00e9sidente, M\u00e9dicaments novateurs Canada<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

La deuxi\u00e8me consultation du CEPMB […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[174],"tags":[],"topic":[],"team-member-id":[],"class_list":["post-9236","post","type-post","status-publish","format-standard","hentry","category-article-fr"],"yoast_head":"\nThe Hill Times, Lettre \u00e0 l\u2019\u00e9diteur - Innovative Medicines Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Hill Times, Lettre \u00e0 l\u2019\u00e9diteur - Innovative Medicines Canada\" \/>\n<meta property=\"og:description\" content=\"La deuxi\u00e8me consultation du CEPMB [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovative Medicines Canada\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-02T17:26:53+00:00\" \/>\n<meta name=\"author\" content=\"kshaver\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"kshaver\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/\",\"url\":\"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/\",\"name\":\"The Hill Times, Lettre \u00e0 l\u2019\u00e9diteur - Innovative Medicines Canada\",\"isPartOf\":{\"@id\":\"https:\/\/innovativemedicines.ca\/fr\/#website\"},\"datePublished\":\"2020-07-02T17:26:53+00:00\",\"author\":{\"@id\":\"https:\/\/innovativemedicines.ca\/fr\/#\/schema\/person\/83cc7fde450d724bd48db7a80966da67\"},\"breadcrumb\":{\"@id\":\"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/innovativemedicines.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Newsroom\",\"item\":\"https:\/\/innovativemedicines.ca\/fr\/newsroom\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Blog\",\"item\":\"https:\/\/innovativemedicines.ca\/fr\/?page_id=9368\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"The Hill Times, Lettre \u00e0 l\u2019\u00e9diteur\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/innovativemedicines.ca\/fr\/#website\",\"url\":\"https:\/\/innovativemedicines.ca\/fr\/\",\"name\":\"Innovative Medicines Canada\",\"description\":\"Transforming Canadians\u2019 lives\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/innovativemedicines.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/innovativemedicines.ca\/fr\/#\/schema\/person\/83cc7fde450d724bd48db7a80966da67\",\"name\":\"kshaver\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/innovativemedicines.ca\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/eab3dbc67c48deba17de1519e3326397?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/eab3dbc67c48deba17de1519e3326397?s=96&d=mm&r=g\",\"caption\":\"kshaver\"},\"url\":\"https:\/\/innovativemedicines.ca\/fr\/blog\/author\/kshaver\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Hill Times, Lettre \u00e0 l\u2019\u00e9diteur - Innovative Medicines Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/","og_locale":"fr_FR","og_type":"article","og_title":"The Hill Times, Lettre \u00e0 l\u2019\u00e9diteur - Innovative Medicines Canada","og_description":"La deuxi\u00e8me consultation du CEPMB [...]","og_url":"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/","og_site_name":"Innovative Medicines Canada","article_published_time":"2020-07-02T17:26:53+00:00","author":"kshaver","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"kshaver","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/","url":"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/","name":"The Hill Times, Lettre \u00e0 l\u2019\u00e9diteur - Innovative Medicines Canada","isPartOf":{"@id":"https:\/\/innovativemedicines.ca\/fr\/#website"},"datePublished":"2020-07-02T17:26:53+00:00","author":{"@id":"https:\/\/innovativemedicines.ca\/fr\/#\/schema\/person\/83cc7fde450d724bd48db7a80966da67"},"breadcrumb":{"@id":"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/innovativemedicines.ca\/fr\/actualites\/blogues\/the-hill-times-lettre-a-lediteur\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/innovativemedicines.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Newsroom","item":"https:\/\/innovativemedicines.ca\/fr\/newsroom\/"},{"@type":"ListItem","position":3,"name":"Blog","item":"https:\/\/innovativemedicines.ca\/fr\/?page_id=9368"},{"@type":"ListItem","position":4,"name":"The Hill Times, Lettre \u00e0 l\u2019\u00e9diteur"}]},{"@type":"WebSite","@id":"https:\/\/innovativemedicines.ca\/fr\/#website","url":"https:\/\/innovativemedicines.ca\/fr\/","name":"Innovative Medicines Canada","description":"Transforming Canadians\u2019 lives","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/innovativemedicines.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/innovativemedicines.ca\/fr\/#\/schema\/person\/83cc7fde450d724bd48db7a80966da67","name":"kshaver","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/innovativemedicines.ca\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/eab3dbc67c48deba17de1519e3326397?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eab3dbc67c48deba17de1519e3326397?s=96&d=mm&r=g","caption":"kshaver"},"url":"https:\/\/innovativemedicines.ca\/fr\/blog\/author\/kshaver\/"}]}},"_links":{"self":[{"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/posts\/9236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/comments?post=9236"}],"version-history":[{"count":0,"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/posts\/9236\/revisions"}],"wp:attachment":[{"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/media?parent=9236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/categories?post=9236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/tags?post=9236"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/topic?post=9236"},{"taxonomy":"team-member-id","embeddable":true,"href":"https:\/\/innovativemedicines.ca\/fr\/wp-json\/wp\/v2\/team-member-id?post=9236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}